Chiusura precedente | 262,75 |
Aperto | 264,21 |
Denaro | 268,91 x 100 |
Lettera | 269,07 x 100 |
Min-Max giorno | 260,68 - 269,38 |
Intervallo di 52 settimane | 211,71 - 329,72 |
Volume | |
Media Volume | 2.933.420 |
Capitalizzazione | 144,248B |
Beta (5 anni mensile) | 0,60 |
Rapporto PE (ttm) | 21,55 |
EPS (ttm) | 12,48 |
Prossima data utili | 02 mag 2024 |
Rendimento e dividendo (futuro) | 9,00 (3,43%) |
Data ex dividendo | 16 mag 2024 |
Stima target 1A | 306,20 |
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic
Collaboration Brings Together TScan’s Proprietary Target Discovery Platform and Amgen’s Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million THOUSAND OAKS, Calif. and WALTHAM, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan’s proprietary target discovery